KR KRSNAA
Krsnaa Diagnostics Q4 2026
KRKRSNAA

Krsnaa Diagnostics Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 26 May 2026

Management summary

  • Krsnaa Diagnostics delivered strong financial results for Q4 and FY26, with significant revenue and PAT growth driven by its integrated diagnostic platform and expanding retail network.
  • The company improved its working capital efficiency by reducing DSO and made substantial capital investments for future growth, including the Rajasthan project and MRI expansions.
  • While acknowledging some short-term operational pressures and receivables delays, management expressed confidence in maintaining profitability and achieving ambitious growth targets, particularly in retail and new geographies.

Source: Inve concall analysis and management guidance record.

Highlights

  • FY26 Revenue stood at approximately INR 7,728 million, demonstrating resilient growth.

  • FY26 PAT grew significantly to approximately INR 1,014 million, marking the first time crossing INR 1,000 million.

  • Q4 PAT alone stood at approximately INR 417 million, growing over 101% year-on-year.

  • Days Sales Outstanding (DSO) reduced from 155 days in Q3 to 139 days in Q4 FY26, reflecting improved collections and working capital efficiency.

What they filed

Q4 FY26: revenue down 110.0%, net profit up 104.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue9 10 8 2 -3 −133%-1 −110%
EBITDA48 53 50 58 48 +0%57 +8%
Net profit22 21 20 23 16 −27%43 +105%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • Rajasthan Revenue Potential Revenue · FY27 · Medium confidence INR 100-150 crores

Retail Contribution

  • Retail Contribution to Overall Revenue Retail Contribution · FY27 · Medium confidence double digits

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
Rajasthan project contribution and ramp-up timeline Direct
So in this quarter, there was no contribution of Rajasthan. We were all in the phase of establishing the labs and the collection centers. We see Rajasthan contribution coming in from Q1 FY '27. The revenues have started coming up. The entire installation is expected to be complet

Clarifies that Rajasthan, a major growth driver, will start contributing from Q1 FY27 and be fully operational by Q2 FY27, impacting future revenue.

Asked by Bala Murali Krishna

Retail business Q-o-Q performance and margin sustainability Partial
Sure. So Mr. Bala, on the retail side, I'll ask Mitesh to answer the query. With regards to the margin profile, we are working towards maintaining the current level of EBITDA margins. There might be some impact in the Q1 where there is upfront deployment of manpower.

Addresses concerns about flat retail revenue QoQ and potential short-term margin pressure in Q1 FY27 due to manpower deployment for expansion.

Asked by Bala Murali Krishna

Unlock risks & concerns, Q1 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 6 risks, concerns & management red flags
  • 5 watchlist triggers for Q1 FY27
  • +7 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image